For years prognosis in SCLC has remained dismal, now we have wealth of agents to watch out for
A critique of the latest data in EGFR mt NSCLC - where differences are beginning to emerge
It’s time to take five lung cancer trials, put them through their paces and explain why all may not…
A deeper look at the latest PD-L1 x VEGF bispecific data
All aboard to hear more about novel targeted therapy combination strategies...
A primer on neoantigens and their importance in cancer research
First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.
